NuVasive Announces Definitive Settlement With United States
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
NuVasive (NUVA) PT Raised to $65 at Leerink Partners Amid Solid Q2
July 29, 2015 7:59 AM EDTLeerink Partners analyst Richard Newitter reiterated an Outperform rating and boosted his price target on NuVasive (NASDAQ: NUVA) to $65.00 (from $57.00) following solid Q2 results.
Newitter commented, "NUVA's 2Q was solid with 8.5% cc rev growth & margin/EPS upside. 2015 guidance (rev unchgd; mgn/EPS... More
Brean Capital Raises Price Target on NuVasive (NUVA) Following 2Q EPS Beat
July 29, 2015 7:35 AM EDTBrean Capital reiterated a Buy rating on NuVasive (NASDAQ: NUVA), and raised the price target to $56.00 (from $55.00), following a 2Q15 EPS beat. NUVA reported non-GAAP EPS of $0.31, $0.06 above consensus estimates of $0.25. Revenues for the quarter came in at $202.9M, versus consensus of $200.7M. NUVA... More
NuVasive (NUVA) Reports Settlement with DOJ
July 28, 2015 5:15 PM EDTNuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, announced today that it has reached a definitive settlement with the U.S. Department of Justice ("DOJ") related to the subpoena issued to the Company by the Office of Inspector General of the Department of Health and... More
NuVasive (NUVA) Tops Q2 EPS by 6c; Enters Settlement with U.S. DOJ
July 28, 2015 4:39 PM EDTNuVasive (NASDAQ: NUVA) reported Q2 EPS of $0.31, $0.06 better than the analyst estimate of $0.25. Revenue for the quarter came in at $202.9 million versus the consensus estimate of $200.71 million.
NuVasive sees FY2015 EPS of $1.17, versus the consensus of $1.12. NuVasive sees FY2015 revenue of $810.0 million, versus the consensus of $812.2 million.
The company also has reached a definitive settlement with the U.S. Department... More
